Simethicone helps break up gas bubbles in your stomach and intestines to relieve bloating, pressure, and discomfort from excess gas.[1] Gas-X is currently being investigated across 6 indications[3], with its most advanced program in Phase 3.[1]
Gas-X is one of 152 small molecule programs targeting Dyspepsia. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
949 competitors in Colorectal Cancer
Gas-X
Eylea
Emend IV
PORTRAZZA
Ketalar
Xylocaine
Versed
Ultiva
Bridion
Andriol
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details